Evidence map›Paper›PMID 42599619›Full record

ArticleJournal of neuro-oncology2026

Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.

Mark A Damante, Ryan B Juncker, Andrew S Little, Jamie J Van Gompel, Sandhya Palit, Donato R Pacione, Garni Barkhoudarian, Walavan Sivakumar, Spiros Blackburn, Michelle Magaña Mendoza and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mark A Damante *Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Ryan B Juncker *College of Medicine, The Ohio State University, Columbus, OH, USA.
Andrew S LittleDepartment of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Jamie J Van GompelDepartment of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
Sandhya PalitDepartment of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
Donato R PacioneDepartment of Neurosurgery, New York University, New York, NY, USA.
Garni BarkhoudarianDepartment of Neurosurgery, Pacific Neuroscience Institute, Providence St. Johns Medical Center, Santa Monica, CA, USA.
Walavan SivakumarDepartment of Neurosurgery, Pacific Neuroscience Institute, Providence St. Johns Medical Center, Santa Monica, CA, USA.
Spiros BlackburnDepartment of Neurosurgery, UT Health Houston, Houston, TX, USA.
Michelle Magaña MendozaNeuroanalytics Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
James J EvansDepartment of Neurosurgery, Jefferson University, Philadelphia, PA, USA.
Carolina BenjaminDepartment of Neurological Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Joshua D PalmerDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Pierre GiglioDivision of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Daniel M PrevedelloDepartment of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Kyle C WuDepartment of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA. kyle.wu@osumc.edu.
RAPID Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTargeted therapy for BRAF V600E mutant papillary craniopharyngioma (PCP) has been rapidly accepted, though given the rarity of the tumor, there is limited guidance for appropriate use. Here, we retrospectively evaluated current practice patterns for the implementation of targeted therapeutics and their outcomes in the treatment of papillary craniopharyngioma (PCP).

methodsPractice patterns at the institutions in the Registry for Adenomas of the Pituitary and Related Disorders (RAPID) for treatment of BRAF V600E mutated PCPs using targeted therapy were evaluated. Baseline clinical and demographic variables were retrospectively recorded. Imaging response was evaluated. Dosing, treatment course, adverse events (AEs) and other therapeutic strategies employing BRAF/MEK inhibitors were studied. Adjuvant and/or salvage therapies, including radiation and surgery were recorded.

resultsMost patients demonstrated at least partial response to BRAF and/or BRAF/MEK inhibition (13/19, 72.2%). No patients progressed through therapy. Grade 0-2 AEs occurred in 79% of cases, and nine (47.4%) patients eventually discontinued therapy. Radiation-sparing regimens demonstrated similar radiographic response rates and had smaller residual tumor volume after treatment completion (23.7 vs. 612.4 mm

conclusionCritical insights into molecular therapeutic practice patterns for treatment of PCP were identified. Radiation-sparing, mono-therapeutic, and prolonged treatment duration are feasible options and warrant further study.

Indexed as

CraniopharyngiomaMolecular Targeted TherapyPituitary NeoplasmsPractice Patterns, Physicians'AdolescentAdultAgedChildChild, PreschoolFemaleFollow-Up StudiesHumansMaleMiddle AgedMutationProto-Oncogene Proteins B-rafBRAF protein, humanProto-Oncogene Proteins B-rafBRAF V600ECraniopharyngiomaPapillary craniopharyngiomaRadiationTargeted therapy

Identifiers

PMID42599619
PMCPMC13476336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.